Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Sativex® Approved In Denmark For The Treatment Of Spasticity Due To Multiple Sclerosis
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Sativex® Approved In Denmark For The Treatment Of Spasticity Due To Multiple Sclerosis
Admin Wed Jun 08, 2011 8:45 am
Sativex® Approved In Denmark For The Treatment Of Spasticity Due To Multiple Sclerosis
Almirall, S.A. (ALM:MC) and GW Pharmaceuticals plc (AIM:GWP) today announced that the health authorities in Denmark have granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as an add-on therapy for the treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medication
Approval in Denmark follows successful completion in March 2011 of the European Mutual Recognition Procedure (MRP) with all countries involved recommending approval. Approval for Sativex® was granted in Germany on 26th May 2011 and the product is expected to be launched there in July. In addition to Germany and Denmark, launch is also expected in Sweden before the end of 2011. Launches in Italy, Czech Republic and Austria are expected in 2012.
For Deatils ---> Click Here
Almirall, S.A. (ALM:MC) and GW Pharmaceuticals plc (AIM:GWP) today announced that the health authorities in Denmark have granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as an add-on therapy for the treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medication
Approval in Denmark follows successful completion in March 2011 of the European Mutual Recognition Procedure (MRP) with all countries involved recommending approval. Approval for Sativex® was granted in Germany on 26th May 2011 and the product is expected to be launched there in July. In addition to Germany and Denmark, launch is also expected in Sweden before the end of 2011. Launches in Italy, Czech Republic and Austria are expected in 2012.
For Deatils ---> Click Here
Admin- Admin
- Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia -
Similar topics» Q- Which of these medications are FDA Approved for treatment of Alcohol Dependence?
» New SNRI Approved by FDA: Levomilnacipran
» Viibryd- New Antidepressant approved by FDA recently
» Mood Disorders- Multiple Choice Questions Thread
» Lisdexamfetamine Dimesylate: Only Stimulant Approved by FDA for ADHD Maintenance.
» New SNRI Approved by FDA: Levomilnacipran
» Viibryd- New Antidepressant approved by FDA recently
» Mood Disorders- Multiple Choice Questions Thread
» Lisdexamfetamine Dimesylate: Only Stimulant Approved by FDA for ADHD Maintenance.
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
» L-Methylfolate: Who Will benefit
» Vitamins & Supplements in Clinical Practice.
» Imaging Biomarkers for Outcomes in Mild TBI
» Q.5 Clozapine Neutopenia
» Treating Disorders!
» Cortical Abnormalities in Adults & Adolescents with MDD
» Efficacy of Antipsychotics in Pediatric Acute Mania
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?